Palpebral Non-Hodgkin Lymphoma with Non-specific Reactive Hepatitis

Pradana Zaky Romadhon, Bagus Aulia Mahdi, Ugroseno Yudho Bintoro

Abstract

ABSTRACT

 

Extranodal Non-Hodgkin Lymphoma (NHL) remains an odd issue and something to discuss. Clinical evidence and guidelines on the treatment have not yet been broadly published and accessible. Here, we present a case of a thirty-eight years old woman complaining of mass on both lower lids of the eyes. The CT Scan examination showed enhancing solid masses on right-sided and left-sided palpebra inferior that press bulb oculi, suspected as bilateral malignant masses of bilateral palpebra inferior. Laboratory data revealed the surge of liver function marker. The patient was eventually diagnosed with Non-Hodgkin Lymphoma (NHL) of palpebra inferior B cell type high-grade stadium II E. Although there are still ongoing research and development of definitive treatments, R-CHOP a regiment given to this patient has shown complete favorable result with dosage adjustment due to the surge of basal liver function. The regiment was considered safe since no adverse effects reported

Keywords: extranodal, lymphoma non-hodgkin, palpebra, liver function

Keywords

case report

Full Text:

PDF

References

Amit, S., Purwar, N., Agarwal, A., & Kanchan, S. (2012). Primary orbital non-Hodgkin's lymphoma. BMJ Case Rep, 2012. doi:10.1136/bcr-2012-006847

Ashariati, A. (2015). Kemoterapi. In A. Tjokorprawiro, P. B. Setiawan, C. Effendi, D. Santoso, & G. Soegiarto (Eds.), Buku Ajar Ilmu Penyakit Dalam (pp. 433-436). Surabaya: Airlangga University Press.

Borghi, A., Caselli, E., Di Luca, D., Sebastiani, A., Perri, P., Seraceni, S., . . . Virgili, A. (2013). Detection of Chlamydophila pneumoniae and human herpesvirus 8 in primary cutaneous anaplastic large-cell lymphoma: a case report. Infectious agents and cancer, 8(1), 41-41. doi:10.1186/1750-9378-8-41

Chihara, D., Oki, Y., Fanale, M. A., Westin, J. R., Nastoupil, L. J., Neelapu, S., . . . Cheah, C. Y. (2019). Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol, 185(2), 334-338. doi:10.1111/bjh.15444

Chu, E., & DeVita, V. T. (2018). Physicians Cancer Chemotherapy Drug Manual. Wall Street Burlington, USA: Jones & Barlett Learning.

Eckardt, A. M., Lemound, J., Rana, M., & Gellrich, N. C. (2013). Orbital lymphoma: diagnostic approach and treatment outcome. World J Surg Oncol, 11, 73. doi:10.1186/1477-7819-11-73

Hahn, J. S., Kim, C., Min, Y. H., Ko, Y. W., Suh, C. O., & Park, Y. Y. (2001). Non-Hodgkin's lymphoma & primary biliary cirrhosis with Sjögren's syndrome. Yonsei Med J, 42(2), 258-263. doi:10.3349/ymj.2001.42.2.258

Hendrayana, T., Wilmer, A., Kurth, V., Schmidt-Wolf, I., & Jaehde, U. (2017). Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Scientia Pharmaceutica, 85(1), 8. doi:10.3390/scipharm85010008

Marcus, R., Sweetenham, J. W., & Williams, M. (2014). Lymphoma : Pathology, Diagnosis, and Treatment (Second ed.): Cambridge University Press.

Mbulaiteye, S. M., Parkin, D. M., & Rabkin, C. S. (2003). Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am, 17(3), 673-696, v. doi:10.1016/s0889-8588(03)00048-0

Nanthakwang, N., Rattarittamrong, E., Rattanathammethee, T., Chai-Adisaksopha, C., Tantiworawit, A., Norrasethada, L., & Ya-In, C. (2019). Clinicopathological study and outcomes of primary extranodal lymphoma. Hematol Rep, 11(4), 8227. doi:10.4081/hr.2019.8227

Nola, M., Lukenda, A., Bollmann, M., Kalauz, M., Petrovecki, M., & Bollmann, R. (2004). Outcome and prognostic factors in ocular adnexal lymphoma. Croat Med J, 45(3), 328-332.

Nutting, C. M., Shah-Desai, S., Rose, G. E., Norton, A. P., & Plowman, P. N. (2006). Thyroid orbitopathy possibly predisposes to late-onset of periocular lymphoma. Eye (Lond), 20(6), 645-648. doi:10.1038/sj.eye.6702027

Olsen, T. G., Holm, F., Mikkelsen, L. H., Rasmussen, P. K., Coupland, S. E., Esmaeli, B., . . . Heegaard, S. (2019). Orbital Lymphoma-An International Multicenter Retrospective Study. Am J Ophthalmol, 199, 44-57. doi:10.1016/j.ajo.2018.11.002

Pfeffer, M. R., Rabin, T., Tsvang, L., Goffman, J., Rosen, N., & Symon, Z. (2004). Orbital lymphoma: is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys, 60(2), 527-530. doi:10.1016/j.ijrobp.2004.03.039

Priego, G., Majos, C., Climent, F., & Muntane, A. (2012). Orbital lymphoma: imaging features and differential diagnosis. Insights Imaging, 3(4), 337-344. doi:10.1007/s13244-012-0156-1

Skeel, T. R., & Khleif, S. N. (2011). Handbook of Cancer Chemotherapy (Eighth Edition ed.). Philadelphia, PA 19103: Lippincott Williams & Wilkins, a Wolters Kluwer business.

Svendsen, F. H., Rasmussen, P. K., Coupland, S. E., Esmaeli, B., Finger, P. T., Graue, G. F., . . . Heegaard, S. (2017). Lymphoma of the Eyelid - An International Multicenter Retrospective Study. Am J Ophthalmol, 177, 58-68. doi:10.1016/j.ajo.2017.02.004

Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., . . . Ladetto, M. (2015). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26, v116-v125. doi:10.1093/annonc/mdv304

Vallinayagan, M., Krishnamoorthy, J., Vijayakumar, V., & Suryawanashi, D. (2017). Bilateral Primary Orbital Non Hodgkin’s Lymphoma Masquerading As Myositic Pseudotumor In An Elderly Patient. Delhi Journal of Opthalmology, 288, 40-42.

Vannata, B., & Zucca, E. (2015). Primary extranodal B-cell lymphoma: current concepts and treatment strategies. Chin Clin Oncol, 4(1), 10. doi:10.3978/j.issn.2304-3865.2014.12.01

Wali, U. K., & Al-Mujaini, A. (2010). Sebaceous gland carcinoma of the eyelid. Oman journal of ophthalmology, 3(3), 117-121. doi:10.4103/0974-620X.71885

Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., . . . Sundar, H. (2019). NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal of the National Comprehensive Cancer Network, 17(6), 650-661. doi:10.6004/jnccn.2019.0029


DOI: http://dx.doi.org/10.30651/jqm.v5i2.7550